Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 3/20 | 0.43 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.41 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.40 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1516708 | 0.89 | AHR (0.41) | AHRTDP1L3MBTL1PARP10PARP11 | |
| SCHEMBL620562 | 0.86 | AHR (0.58) | AHRTDP1L3MBTL1PARP10PARP11 | |
| SCHEMBL8759192 | 0.85 | MAOB (0.43) | AHRALDH2ALDH3A1TDP1L3MBTL1 | |
| SCHEMBL3335046 | 0.82 | MAOA (0.45) | AHRSIRT2METAP1 | |
| SCHEMBL30697936 | 0.82 | MAOA (0.45) | AHRSIRT2METAP1 | |
| SCHEMBL619709 | 0.78 | AHR (0.56) | AHRTDP1L3MBTL1PARP10PARP11 | |
| SCHEMBL14054458 | 0.77 | AHR (0.43) | AHRTDP1L3MBTL1PARP10PARP11 | |
| SCHEMBL5859179 | 0.77 | ALDH2 (0.41) | ALDH2ALDH3A1KDM4ECYP1A2GLA | |
| SCHEMBL32672830 | 0.77 | ALDH2 (0.41) | ALDH2ALDH3A1SRD5A1KDM4ECYP1A2 | |
| SCHEMBL752211 | 0.77 | ALDH2 (0.41) | ALDH2ALDH3A1PARP10SRD5A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113631168-B | GPR35 modulators | 普罗米修斯生物科学公司 | 2024-11-19 | — | — | CN | disclosed |
| EP-3914256-B1 | GPR35 MODULATORS | PROMETHEUS BIOSCIENCES INC (US) | 2024-05-29 | — | — | EP | disclosed |
| US-11827614-B2 | Synthetic pathway to belzutifan and crystalline phases of synthetic intermediates | MERCK SHARP & DOHME LLC (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827614-B2 | Synthetic pathway to belzutifan and crystalline phases of synthetic intermediates | MERCK SHARP & DOHME LLC (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827614-B2 | Synthetic pathway to belzutifan and crystalline phases of synthetic intermediates | MERCK SHARP & DOHME LLC (US) | 2023-11-28 | — | — | US | disclosed |
| US-11773101-B2 | GPR35 modulators | PROMETHEUS BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| CN-112457280-B | Synthesis of terphenyl compounds | 维克图斯生物系统有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-114394980-B | Preparation method of spiro spiroketal compound | 广东省科学院动物研究所 | 2022-12-13 | — | — | CN | disclosed |
| US-20220388974-A1 | NOVEL SYNTHETIC PATHWAY TO BELZUTIFAN AND CRYSTALLINE PHASES OF SYNTHETIC INTERMEDIATES | MERCK SHARP & DOHME LLC (US) | 2022-12-08 | — | — | US | disclosed |
| CN-114539281-B | Spiro spiroketal compound and application thereof in preparation of anti-plasmodium drugs | 广东省科学院动物研究所 | 2022-09-09 | — | — | CN | disclosed |
| CN-101090894-A | Macrocyclic compounds and compositions useful as BACE inhibitors | NOVARTIS AG (CH) | 2007-12-19 | — | — | CN | disclosed |
| WO-2006113432-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
| US-20060131541-A1 | Dihydrocoumarin derivative, liquid crystal composition containing the same, and liquid crystal display device | JNC PETROCHEMICAL CORPORATION (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-0738267-A1 | ACETYLENES DISUBSTITUTED WITH A PHENYL OR HETEROARYL GROUP AND A 2-OXOCHROMANYL, 2-OXOTHIOCHROMANYL OR 2-OXO-1,2,3,4-TETRAHYDROQUINOLINYL GROUP HAVING RETINOID-LIKE ACTIVITY | Allergan (US) | 1996-10-23 | — | — | EP | disclosed |
| WO-1995018803-A1 | ACETYLENES DISUBSTITUTED WITH A PHENYL OR HETEROARYL GROUP AND A 2-OXOCHROMANYL, 2-OXOTHIOCHROMANYL OR 2-OXO-1,2,3,4-TETRAHYDROQUINOLINYL GROUP HAVING RETINOID-LIKE ACTIVITY | ALLERGAN (US) | 1995-07-13 | — | — | WO | disclosed |
| US-5399561-A | Used for treating skin disorders in mammals | ALLERGAN, INC. (US) | 1995-03-21 | — | — | US | disclosed |
| EP-0207605-B1 | HYPOGLYCEMIC THIAZOLIDINEDIONES | PFIZER INC. (US) | 1990-02-07 | — | — | EP | disclosed |
| US-4703052-A | Hypoglycemic thiazolidinediones | PFIZER INC. (US) | 1987-10-27 | — | — | US | disclosed |
| EP-0207605-A1 | Hypoglycemic thiazolidinediones | PFIZER INC. (US) | 1987-01-07 | — | — | EP | disclosed |
| WO-1986007056-A1 | HYPOGLYCEMIC THIAZOLIDINEDIONES | PFIZER INC. (US) | 1986-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060131541-A1 | Dihydrocoumarin derivative, liquid crystal composition containing the same, and liquid crystal display device | HCCS, SCO2, COIL | AHR 606/4885ALDH2 1020/4885ALDH3A1 235/4885 |
| US-11773101-B2 | GPR35 modulators | GPR35, GPR55, GPR65 | AHR 324/4885ALDH2 1378/4885ALDH3A1 3046/4885 |
| US-20220388974-A1 | NOVEL SYNTHETIC PATHWAY TO BELZUTIFAN AND CRYSTALLINE PHASES OF SYNTHETIC INTERMEDIATES | HIF1AN, HIF1A, EGLN2 | AHR 59/4885ALDH2 2198/4885ALDH3A1 1870/4885 |
| US-11827614-B2 | Synthetic pathway to belzutifan and crystalline phases of synthetic intermediates | HIF1AN, HIF1A, EGLN2 | AHR 56/4885ALDH2 2014/4885ALDH3A1 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.